{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064473","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.566652+00:00","generated_at":"2026-05-22T11:38:38.646391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ultragenyx Q1 revenue $139M, reaffirms FY2025 guidance; UX111 PDUFA Aug 18, 2025","bullets":["Q1 total revenue $139M (+28% YoY); net loss $151M ($1.57/share) vs $171M ($2.03) in Q1 2024.","Crysvita revenue $103M (+25% YoY); Dojolvi $17M; Evkeeza $11M; Mepsevii $8.4M.","Reaffirmed FY2025 guidance: total revenue $640-670M, Crysvita $460-480M, Dojolvi $90-100M.","UX111 BLA for Sanfilippo granted Priority Review; PDUFA date Aug 18, 2025; potential H2 launch.","DTX401 BLA for GSDIa expected mid-2025; GTX-102 Ph3 enrollment completion H2 2025; cash $563M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064473","json":"https://secwatch.observer/filing/0000950170-25-064473.json","markdown":"https://secwatch.observer/filing/0000950170-25-064473.md","text":"https://secwatch.observer/filing/0000950170-25-064473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/0000950170-25-064473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025064473/rare-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:38:38.646391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}